Prashant Yadav
About Prashant Yadav
Prashant Yadav is a Senior Research Fellow and Director of the Healthcare Research Initiataive at the William Davidson Institute at the University of Michigan. Previously he was a Professor of Supply Chain Management at the MIT-Zaragoza International Logistics Program and a Research Affiliate at the MIT Center for Transportation and Logistics.
Prashant’s research explores the functioning of pharmaceutical supply chains using a combination of empirical, analytical and qualitative approaches. His more recent work involves supply chains for medicines in sub-Saharan Africa and other resource limited environments . In this work he collaborates closely with leading policy organizations and philanthropic foundations. Prashant serves as a consultant and adviser in the area of pharmaceutical supply chains to the World Bank, World Health Organization, UK Department for International Development, Roll Back Malaria Partnership, Bill and Melinda Gates Foundation, the Medicines for Malaria Venture and many other global health organizations. He is the author of many scientific publications and his work has been featured in prominent print and broadcast media.
Prashant obtained his Bachelor of Engineering from the Indian Institute of Technology, his MBA from the FORE School of Management and his PhD from the University of Alabama. Before academia, Prashant worked for many years in the area of pharmaceutical strategy, analytics and supply chain consulting.
Role(s) / Profession(s)
- Academic
Organization
- University of Michigan
Work Location(s)
- United States
Prashant's Communities
- Health IT
- Malaria Treatment & Prevention Moderator
Language(s)
- English
- Hindi
- Punjabi
- Russian
- Sanskrit
- Spanish
Recent Contributions
-
Prashant Yadav started a discussion "First results from the Tanzania pilot of ACT subsidy published" in the Malaria Treatment & Prevention community.
The first published results from a pilot project to test the impact of subsidizing ACTs in the private sector which can conducted in Tanzania are now available at http://www.plosone.org/article/info:doi/10.1371/journal.pone.0006857 The proportion of consumers purchasing ACT in the intervention districts where prices of ACTs were subsidized by 90% at the distributor level rose from 1% at baseline to 44.2% one year later. Although in a controlled setting this study provides some evidence that subsidizing prices at ...
-
Prashant Yadav started a discussion "Assured Artemisinin Supply System (A2S2)" in the Malaria Treatment & Prevention community.
In the past years we have seen large mismatches between the demand and supply of artemisinin, the key ingredient in ACTs. Artemisinin comes from the artemisia annua plant and the long growing and harvesting cycle implies that we need to project demand upswings well in advance. A new project, the Assured Artemisinin Supply System(A2S2) is being launched with financing from UNITAID to ensure reliable supplies of artemisinin if ACT demand grows as quickly as projected. ...
-
Prashant Yadav replied to "Multiple first-line treatments (MFT) for malaria: Are we ready?" in the Malaria Treatment & Prevention community.
A discussion on this topic will be held in a special session at the Multi Lateral Initiative on Malaria Meeting in Nairobi on Nov 2 from 14:30 to 16:30
-
Prashant Yadav started a discussion "Multiple first-line treatments (MFT) for malaria: Are we ready?" in the Malaria Treatment & Prevention community.
The national treatment policy in most endemic countries is a single first-line therapy for uncomplicated malaria. This strategy may not be the most effective from the perspective of slowing the spread of drug resistance. Some new studies such as (Boni, Smith and Laxminarayan 2008) recommend the use of multiple first-line therapies (MFT) that may delay the emergence of resistance. Many new drugs have now become available within the ACT class and many others are likely ...
-
Prashant Yadav started a discussion "Saliva based diagnosis: still a possibility?" in the Malaria Treatment & Prevention community.
Current lanoratory or RDT based diagnosis for malaria infection requires drawing blood by fingerprick which poses risks and requires special training especially when rolling out RDTs into community health worker networks. I remember visiting the Macha Hospital in Zambia a few years ago where they were trying to develop some saliva based diagnosis. Does anyone know where we stand on this technology?
Recent Recommendations
- None at this time.